arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Mineralys Therapeutics, Inc.

MLYS
$29.42 ▲ +1.12 (+3.96%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
19 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
36
Health
Weak
Bearish
auto_awesome

Analytical Summary

Mineralys Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.5B
Dividend Yield
Revenue Growth
Op. Margin
ROIC -35.3%
FCF / Share $-0.38
Trailing P/E
Price / Book 4.7x
FCF Yield
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Sep 22, 2026.

19-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-39.34M
↑ +6.8%
FCF / Share Free cash flow per share
$-0.38
↑ +19.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
26
Cash Quality
61

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 5 years · 19 quarters